(Q30803396)

26 June 2017

title

Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database (English)

1 reference

26 June 2017

0 references

0 references

5

Kouichi Hosomi

1 reference

26 June 2017

Mitsutaka Takada

1

1 reference

26 June 2017

Mai Fujimoto

series ordinal

2

1 reference

26 June 2017

Kohei Yamazaki

series ordinal

3

1 reference

26 June 2017

Masashi Takamoto

series ordinal

4

1 reference

26 June 2017

publication date

1 June 2014

1 reference

26 June 2017

1 reference

26 June 2017

volume

37

1 reference

26 June 2017

issue

6

1 reference

26 June 2017

page(s)

421-431

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Clinical perspectives of statin-induced rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Effects of atorvastatin on higher functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

A study of statin use in the prevention of cognitive impairment of vascular origin in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Severe irritability associated with statin cholesterol-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Under-reporting of adverse drug reactions : a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Determinants of under-reporting of adverse drug reactions: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

The role of databases in drug postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

A Bayesian neural network method for adverse drug reaction signal generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Data mining of the public version of the FDA Adverse Event Reporting System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Novel statistical tools for monitoring the safety of marketed drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Short-term memory loss associated with rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Cognitive impairment associated with atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Simvastatin-induced decline in cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Sleep loss and daytime sleepiness in the general adult population of Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Insomnia and its treatment. Prevalence and correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Sleep problems and their correlates in a working population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Prevalence, burden, and treatment of insomnia in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Quantitative signal detection using spontaneous ADR reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0163-X

Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.

21 January 2018

1 reference

12 December 2020

Low serum cholesterol and suicide

1 reference

12 December 2020

HMG-CoA reductase inhibitors for hypercholesterolemia

1 reference

12 December 2020

The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization

1 reference

12 December 2020

Use of antiepileptic drugs and risk of hypothyroidism

1 reference

12 December 2020

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1 reference

12 December 2020

Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia

1 reference

12 December 2020

Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular disease

1 reference

12 December 2020

Risk factors for rhabdomyolysis with simvastatin and atorvastatin

1 reference

12 December 2020

Statin-associated rhabdomyolysis

1 reference

12 December 2020

Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?

1 reference

12 December 2020

Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis

1 reference

12 December 2020

10.1007/S40264-014-0163-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 June 2017

1053202393

0 references

1 reference